AI in Pathology: What could possibly go wrong?


Journal

Seminars in diagnostic pathology
ISSN: 0740-2570
Titre abrégé: Semin Diagn Pathol
Pays: United States
ID NLM: 8502262

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 07 02 2023
revised: 25 02 2023
accepted: 26 02 2023
pubmed: 8 3 2023
medline: 16 3 2023
entrez: 7 3 2023
Statut: ppublish

Résumé

The field of medicine is undergoing rapid digital transformation. Pathologists are now striving to digitize their data, workflows, and interpretations, assisted by the enabling development of whole-slide imaging. Going digital means that the analog process of human diagnosis can be augmented or even replaced by rapidly evolving AI approaches, which are just now entering into clinical practice. But with such progress comes challenges that reflect a variety of stressors, including the impact of unrepresentative training data with accompanying implicit bias, data privacy concerns, and fragility of algorithm performance. Beyond such core digital aspects, considerations arise related to difficulties presented by changing disease presentations, diagnostic approaches, and therapeutic options. While some tools such as data federation can help with broadening data diversity while preserving expertise and local control, they may not be the full answer to some of these issues. The impact of AI in pathology on the field's human practitioners is still very much unknown: installation of unconscious bias and deference to AI guidance need to be understood and addressed. If AI is widely adopted, it may remove many inefficiencies in daily practice and compensate for staff shortages. It may also cause practitioner deskilling, dethrilling, and burnout. We discuss the technological, clinical, legal, and sociological factors that will influence the adoption of AI in pathology, and its eventual impact for good or ill.

Identifiants

pubmed: 36882343
pii: S0740-2570(23)00017-5
doi: 10.1053/j.semdp.2023.02.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100-108

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Keisuke Nakagawa (K)

UC Davis Health, Sacramento, CA.

Lama Moukheiber (L)

Massachusetts Institute of Technology, Cambridge, MA.

Leo A Celi (LA)

Massachusetts Institute of Technology, Cambridge, MA.

Malhar Patel (M)

Rhino Health, Boston, MA.

Faisal Mahmood (F)

Brigham and Women's Hospital, Boston, MA.

Dibson Gondim (D)

University of Louisville, Lousville, KY.

Michael Hogarth (M)

UC San Diego, San Diego, CA.

Richard Levenson (R)

UC Davis Health, Sacramento, CA. Electronic address: rmlevenson@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH